 |
26 Diseases |  |
5 Trials |
|
5 Trials |  |
175 News |  |
| «123» |
- | onalespib (AT13387) / Otsuka
Trial primary completion date: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL (clinicaltrials.gov) - Oct 5, 2020
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2020 --> Oct 2021
- | AT7519 / Novartis, Otsuka, onalespib (AT13387) / Otsuka
Trial completion, Surgery, Metastases: Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 19, 2020
P1, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2020 --> Oct 2021 Active, not recruiting --> Completed
- || abiraterone acetate / Generic mfg., onalespib (AT13387) / Otsuka
Clinical, P1/2 data, PK/PD data, Journal, Combination therapy: Pharmacodynamic and clinical results from a phase 1/2 study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer. (Pubmed Central) - Sep 17, 2020
HSP72 was significantly up-regulated following onalespib treatment, but only a modest decrease in AR and GR was shown in paired pre- and post-treatment tumor biopsy samples. No subjects showed an objective or PSA response Onalespib in combination with AA/P, showed mild evidence of some biological effect, however this effect did not translate into clinical activity, hence further exploration of this combination was not justified.
- | onalespib (AT13387) / Otsuka
Trial primary completion date, Metastases: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 21, 2020
P1/2, N=46, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
No subjects showed an objective or PSA response Onalespib in combination with AA/P, showed mild evidence of some biological effect, however this effect did not translate into clinical activity, hence further exploration of this combination was not justified. Trial primary completion date: Jun 2020 --> Jan 2021
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca, onalespib (AT13387) / Otsuka
Trial completion date, Trial primary completion date, Surgery, Metastases: Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (clinicaltrials.gov) - Jun 4, 2020
P1, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2020 --> Jan 2021 Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020
- Anti-tumor effect and HIF1α inhibition by combining CDK4 inhibitor with HSP90 inhibitor in various cancer types including Rb-deficient tumor cells (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_321;
Multiple HSP90 inhibitors have been tested, including ganetespib, onalespib, XL888 and TAS116, which indicates such combinational inhibition as a class effect...Hypoxia sensitizes the Rb-deficient MDA-MB-468 breast cancer cell line to abemaciclib treatment. Our findings suggest a therapeutic potential for utilizing the combination of CDK4 and HSP90 inhibitors in cancer treatment.
- [VIRTUAL] CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors. (Poster Board 339) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1558;
P1
HSP90 inhibition combined with BRAF/MEK inhibition was determined to be safe with evidence of disease control in a heavily pre-treated population of pts with BRAF V600E/K mut solid tumors. Research Funding: U.S. National Institutes of Health
- | onalespib (AT13387) / Otsuka
Trial primary completion date, Combination therapy, Metastases: Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Apr 10, 2020
P1b, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Research Funding: U.S. National Institutes of Health Trial primary completion date: Dec 2019 --> Dec 2020
- | Lutathera (lutetium Lu 177 dotatate) / Novartis, onalespib (AT13387) / Otsuka
Journal: The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells. (Pubmed Central) - Apr 3, 2020
Consequently, the combination of onalespib and 177Lu‑DOTATATE may prove to be a promising strategy with which to improve therapeutic responses in patients with NETs. Further studies investigating this strategy in vivo regarding the therapeutic effects and potential toxicities are warranted to expand these promising findings.
- | SP600125 / BMS, onalespib (AT13387) / Otsuka
Journal: Enhancement by HSP90 inhibitor of PGD2-stimulated HSP27 induction in osteoblasts: suppression of SAPK/JNK and p38 MAP kinase. (Pubmed Central) - Feb 22, 2020
SP600125, an inhibitor of SAPK/JNK, and SB203580, an inhibitor of p38 MAP kinase, suppressed the amplification by onalespib of the PGD-stimulated HSP27 induction. These results strongly suggest that HSP90 plays a negative role in the HSP27 induction stimulated by PGD in osteoblasts, and that the inhibitory effect of HSP90 is mediated through the regulation of SAPK/JNK and p38 MAP kinase.
- | AT7519 / Novartis, Otsuka, onalespib (AT13387) / Otsuka
Trial primary completion date, Surgery, Metastases: Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 5, 2020
P1, N=37, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
These results strongly suggest that HSP90 plays a negative role in the HSP27 induction stimulated by PGD in osteoblasts, and that the inhibitory effect of HSP90 is mediated through the regulation of SAPK/JNK and p38 MAP kinase. Trial primary completion date: Dec 2019 --> Jun 2020
- | onalespib (AT13387) / Otsuka
Trial primary completion date, Metastases: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 27, 2020
P1/2, N=46, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2019 --> Jun 2020 Trial primary completion date: Dec 2019 --> Jun 2020
- | onalespib (AT13387) / Otsuka
Journal: HSP90 inhibitors diminish PDGF-BB-induced migration of osteoblasts via suppression of p44/p42 MAP kinase. (Pubmed Central) - Jan 12, 2020
Onalespib, an HSP90 inhibitor, significantly reduced the PDGF-BB-stimulated migration evaluated by the two types of migration assays...In addition, the phosphorylation of p44/p42 MAP kinase by PDGF-BB was reduced by geldanamycin. Taken together, these results strongly suggest that HSP90 inhibitors suppress the PDGF-BB-induced osteoblast migration through the attenuation of p44/p42 MAP kinase activity.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca, onalespib (AT13387) / Otsuka
Enrollment closed, Surgery, Metastases: Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (clinicaltrials.gov) - Dec 17, 2019
P1, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Taken together, these results strongly suggest that HSP90 inhibitors suppress the PDGF-BB-induced osteoblast migration through the attenuation of p44/p42 MAP kinase activity. Recruiting --> Active, not recruiting
- | onalespib (AT13387) / Otsuka
Enrollment closed: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL (clinicaltrials.gov) - Dec 2, 2019
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Increasing extent of ablation - a senolytic approach to promote apoptosis of latent glioblastoma following chemoradiation. (Ballroom Lawn) - Oct 29, 2019 - Abstract #SNO2019SNO_1272;
Current therapies, including radiation and temozolomide, are known to induce senescence in tumor cells...Given existence of multiple SCAPs, we evaluated the IC50 for several senolytic candidates including Dasatinib, Quercetin, Fisetin, AMG-232, Onalespib, A1331852, and Navitoclax in radiated vs non-radiated cells... Our findings suggest that blocking the anti-apoptotic pathway Bcl-XL in GBM cells rendered at least transiently senescent following radiation may provide an avenue to selectively ablate residual glioblastoma cells following radiation. Our data provide proof of principle that senolytic therapy may represent a previously untapped window of opportunity to increase extent of tumor ablation following completion of standard cytotoxic therapies.
- | ganetespib (ADX-1612) / Aldeyra, onalespib (AT13387) / Otsuka
Journal: High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. (Pubmed Central) - Oct 27, 2019
Combined with castration, ganetespib displayed deeper PDX tumor regressions and delayed castration resistance relative to either monotherapy. In all, comprehensive data from near-patient models presents novel contexts for HSP90 inhibition in multiple CRPC genotypes and phenotypes, expands upon HSP90 inhibitors as simultaneous inhibitors of oncogenic signaling and resistance mechanisms, and suggests utility for combined HSP90/AR inhibition in CRPC.
- | onalespib (AT13387) / Otsuka
Trial primary completion date: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL (clinicaltrials.gov) - Oct 20, 2019
P2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
In all, comprehensive data from near-patient models presents novel contexts for HSP90 inhibition in multiple CRPC genotypes and phenotypes, expands upon HSP90 inhibitors as simultaneous inhibitors of oncogenic signaling and resistance mechanisms, and suggests utility for combined HSP90/AR inhibition in CRPC. Trial primary completion date: Aug 2019 --> Oct 2020
- | onalespib (AT13387) / Otsuka
Trial primary completion date, Metastases: Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin (clinicaltrials.gov) - Oct 17, 2019
P1, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2019 --> Oct 2020 Trial primary completion date: Sep 2019 --> Sep 2020
- | onalespib (AT13387) / Otsuka
Enrollment closed, Combination therapy, Metastases: Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Oct 16, 2019
P1b, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2019 --> Sep 2020 Recruiting --> Active, not recruiting
- | AT7519 / Novartis, Otsuka, onalespib (AT13387) / Otsuka
Enrollment closed, Surgery, Metastases: Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 2, 2019
P1, N=37, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- paclitaxel / Generic Mfg., onalespib (AT13387) / Otsuka
Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2089;
P1b
MTD of onalespib in combination with standard dose and schedule of paclitaxel was determined to be 260 mg/m2. Dose expansion study at MTD is currently ongoing.
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene, onalespib (AT13387) / Otsuka
Enrollment change, Combination therapy, Surgery, Metastases: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 11, 2019
P1, N=22, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Dose expansion study at MTD is currently ongoing. N=32 --> 22
- | onalespib (AT13387) / Otsuka
Trial primary completion date, Metastases: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 2, 2019
P1/2, N=46, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=32 --> 22 Trial primary completion date: Jun 2019 --> Dec 2019
- | AT7519 / Novartis, Otsuka, onalespib (AT13387) / Otsuka
Trial primary completion date, Surgery, Metastases: Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 2, 2019
P1, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2019 --> Dec 2019 Trial primary completion date: Jun 2019 --> Dec 2019
- ||||| onalespib (AT13387) / Otsuka
Congrats to #OSUCOM professors @vpuduvalli MBBS, and Deepa Sampath, PhD, who were awarded an @NIH grant to explore the effects of a targeted drug called onalespib on #glioblastoma. #MeetOSUCOM (Twitter) - Apr 18, 2019
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene, onalespib (AT13387) / Otsuka
Enrollment closed, Trial primary completion date, Combination therapy, Surgery, Metastases: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 16, 2019
P1, N=32, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Mar 2019
- | onalespib (AT13387) / Otsuka
Trial completion date, Metastases: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2019
P1/2, N=46, Recruiting, Sponsor: National Cancer Institute (NCI)
- | onalespib (AT13387) / Otsuka
Trial primary completion date, Metastases: Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin (clinicaltrials.gov) - Dec 14, 2018
P1, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Mar 2019 Trial primary completion date: Sep 2018 --> Sep 2019
- | AT7519 / Novartis, Otsuka, onalespib (AT13387) / Otsuka
Trial primary completion date, Surgery, Metastases: Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 11, 2018
P1, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2018 --> Sep 2019 Trial primary completion date: Jun 2018 --> Jun 2019
- | Journal: Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. (Pubmed Central) - Sep 7, 2018
Furthermore, quantitative proteome studies identified 14 types of PTMs with 93 marks on the core histones, including 34 novel histone marks of butyrylation, citrullination, 2-hydroxyisobutyrylation, methylation, O-GlcNAcylation, propionylation, and succinylation in AUY922- and ganetespib-treated 5637 cells. Together, this study outlines the association between proteomic changes and histone PTMs in response to HSP90 inhibitor treatment in bladder carcinoma cells, and thus intensifies the understanding of HSP90 inhibition-mediated bladder cancer therapeutics.
- | onalespib (AT13387) / Otsuka
Enrollment closed, Trial primary completion date, Metastases: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 8, 2018
P1/2, N=46, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Together, this study outlines the association between proteomic changes and histone PTMs in response to HSP90 inhibitor treatment in bladder carcinoma cells, and thus intensifies the understanding of HSP90 inhibition-mediated bladder cancer therapeutics. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jun 2019
- | onalespib (AT13387) / Otsuka
Clinical, Journal, Combination therapy: Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide Against Malignant Gliomas. (Pubmed Central) - May 26, 2018
Onalespib effectively crossed the BBB to inhibit HSP90 invivo and extended survival as a single agent in zebrafish xenografts and in combination with TMZ in both zebrafish and GSC mouse xenografts. Our results demonstrate the long-acting effects of onalespib against gliomas in vitro and in vivo which combined with its ability to cross the BBB support its development as a potential therapeutic agent in combination with TMZ against gliomas.
- |||| onalespib (AT13387) / Otsuka
Trial completion, Combination therapy: A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib (clinicaltrials.gov) - Jan 18, 2018
P1/2, N=228, Completed, Sponsor: Astex Pharmaceuticals
Our results demonstrate the long-acting effects of onalespib against gliomas in vitro and in vivo which combined with its ability to cross the BBB support its development as a potential therapeutic agent in combination with TMZ against gliomas. Active, not recruiting --> Completed
- | onalespib (AT13387) / Otsuka
Enrollment open, Metastases: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 17, 2017
P1/2, N=46, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Recruiting
- | onalespib (AT13387) / Otsuka
Trial primary completion date, Metastases: Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin (clinicaltrials.gov) - Sep 18, 2017
P1, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Trial primary completion date: May 2017 --> Sep 2018
- | AT7519 / Novartis, Otsuka, onalespib (AT13387) / Otsuka
Trial primary completion date, Surgery, Metastases: Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 12, 2017
P1, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2017 --> Sep 2018 Trial primary completion date: Jul 2017 --> Jun 2018
- | onalespib (AT13387) / Otsuka
Trial suspension, Metastases: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 18, 2017
P1/2, N=46, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2017 --> Jun 2018 Recruiting --> Suspended
- | onalespib (AT13387) / Otsuka
Enrollment open, Combination therapy, Metastases: Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Aug 2, 2017
P1b, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Suspended --> Recruiting
- | onalespib (AT13387) / Otsuka
Trial suspension, Combination therapy, Metastases: Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 21, 2017
P1b, N=24, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- | onalespib (AT13387) / Otsuka
Journal: Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. (Pubmed Central) - Jul 9, 2017
P2
The combination of onalespib plus imatinib was well tolerated but exhibited limited antitumour activity as dosed in this TKI-resistant GIST patient population. Trial registration ID: clinicaltrials.gov: NCT01294202.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca, onalespib (AT13387) / Otsuka
Enrollment open, Enrollment change, Trial primary completion date, PARP Biomarker, Surgery, Metastases: Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (clinicaltrials.gov) - Jun 16, 2017
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial registration ID: clinicaltrials.gov: NCT01294202. Not yet recruiting --> Recruiting | N=60 --> 40 | Trial primary completion date: Oct 2019 --> Jun 2020
- | onalespib (AT13387) / Otsuka
Trial primary completion date, Metastases: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 18, 2017
P1/2, N=52, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | N=60 --> 40 | Trial primary completion date: Oct 2019 --> Jun 2020 Trial primary completion date: Jan 2017 --> Jun 2018
- | onalespib (AT13387) / Otsuka
Trial primary completion date, Combination therapy, Metastases: Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Apr 14, 2017
P1b, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2017 --> Jun 2018 Trial primary completion date: Mar 2017 --> Jan 2018
- | onalespib (AT13387) / Otsuka
Trial primary completion date: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL (clinicaltrials.gov) - Feb 20, 2017
P2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2017 --> Jan 2018 Trial primary completion date: Dec 2016 --> Aug 2019
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene, onalespib (AT13387) / Otsuka
Trial primary completion date, Combination therapy, Surgery, Metastases: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 31, 2017
P1, N=32, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Aug 2019 Trial primary completion date: Dec 2016 --> Jun 2018
- onalespib (AT13387) / Otsuka
Enrollment change: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL (clinicaltrials.gov) - Dec 16, 2016
P2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Jun 2018 N=34 --> 50
- Lynparza (olaparib) / Merck (MSD), AstraZeneca, onalespib (AT13387) / Otsuka
New P1 trial, PARP Biomarker, Surgery, Metastases: Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (clinicaltrials.gov) - Sep 13, 2016
P1, N=60, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- onalespib (AT13387) / Otsuka
Phase classification, Combination therapy, Metastases: Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Aug 9, 2016
P1b, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
N=34 --> 50 Phase classification: P1 --> P1b
- Talzenna (talazoparib) / Pfizer, onalespib (AT13387) / Otsuka
Enrollment change, Trial withdrawal, PARP Biomarker, Metastases: Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 27, 2016
P1, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Phase classification: P1 --> P1b N=40 --> 0 | Not yet recruiting --> Withdrawn